Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Isoleucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 12/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoleucine SCHEMBL599450 | 1.00 | SLC7A5 (0.50) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL5973421 | 0.95 | SLC7A5 (0.55) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL8868 | 0.95 | — | — | |
| Isoleucine SCHEMBL2783498 | 0.95 | SLC7A5 (0.55) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL1255582 | 0.95 | SLC7A5 (0.55) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL1255583 | 0.95 | SLC7A5 (0.55) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL8045737 | 0.95 | SLC7A5 (0.55) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL8186739 | 0.95 | SLC7A5 (0.55) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL8043620 | 0.95 | SLC7A5 (0.55) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL20340795 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948199-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LAB INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8114440-B2 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100240741-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LABORATORIES, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7754679-B2 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1948199-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX Laboratories Inc (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007058801-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LABORATORIES INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070110827-A1 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070111969-A1 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240741-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | PHOSPHO1, SGMS1, PCYT1A | SLC7A5 228/4885DPP4 1254/4885DPP8 1104/4885 |
| US-20070111969-A1 | Pharmaceutical compositions for the administration of aptamers | PHOSPHO1, SGMS1, PCYT1A | SLC7A5 228/4885DPP4 1254/4885DPP8 1104/4885 |
| US-20070110827-A1 | Pharmaceutical compositions for the administration of aptamers | PHOSPHO1, SGMS1, PCYT1A | SLC7A5 228/4885DPP4 1254/4885DPP8 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.